A Different EGFR Mutation (EGFR Exon 20) Requires New Treatment Approaches in NSCLC: The identification of specific genetic alterations has led to a precision treatment approach in non-small cell lung cancer. Epidermal growth factor receptor (EGFR) mutations that target exon 19 and exon 21 are sensitive to tyrosine kinase inhibitors (TKIs). In contrast, EGFR exon 20 insertion mutations account for 3-10% of EGFR mutations and are associated with a poor response to previously available TKI therapies 1. As part of this presentation, we will discuss relevant literature, guidelines, and emerging data for the treatment of NSCLC with EGFR exon 20 insertion mutations.

Moderator: Ticiana Leal, MD, Emory Winship Cancer Center

Debaters: Alyson Leonard, PharmD, BCPS, BCOP, CPP, Cone Health | Latha Radhakrishnan, PharmD, BCPS, BCOP, University of Illinois Cancer Center